Journal
CLINICAL EPIGENETICS
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13148-021-01147-w
Keywords
Histone modification; Epigenetics; Rhabdomyosarcoma; Cancer; Methyltransferase; EZH2
Categories
Funding
- School in Life Sciences and Biotechnologies at the University of Sassari (PON ricerca e innovazione)
Ask authors/readers for more resources
Muscle differentiation failure may involve epigenetic systems and the PRC2 complex. Research has shown that EZH2 is often deregulated in rhabdomyosarcoma and is associated with tumor malignancy.
Skeletal muscle formation represents a complex of highly organized and specialized systems that are still not fully understood. Epigenetic systems underline embryonic development, maintenance of stemness, and progression of differentiation. Polycomb group proteins play the role of gene silencing of stemness markers that regulate muscle differentiation. Enhancer of Zeste EZH2 is the catalytic subunit of the complex that is able to trimethylate lysine 27 of histone H3 and induce silencing of the involved genes. In embryonal Rhabdomyosarcoma and several other tumors, EZH2 is often deregulated and, in some cases, is associated with tumor malignancy. This review explores the molecular processes underlying the failure of muscle differentiation with a focus on the PRC2 complex. These considerations could open new studies aimed at the development of new cutting-edge therapeutic strategies in the onset of Rhabdomyosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available